Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Korea’s Samsung And Biogen Idec Initiate JV For Global Biosimilars Development

This article was originally published in PharmAsia News

Executive Summary

The $300 million Korean joint venture gives Samsung a global stage but raises questions about its Rituxan biosimilars program.

Advertisement

Related Content

Samsung Will Develop Biosimilars For U.S. And EU, But Avoids Emerging Markets For Now
Samsung Looks To Mirror Fellow Korean Pharma Celltrion's Path From CMO To Biosimilars Developer With Quintiles JV
Nichi-Iko Takes Share Of Korean Biosimilar Firm, Gains Japanese Rights For Remicade And Herceptin Generics

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC077033

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel